PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986

The medicine is dispensed with a doctor's prescription only

ERIVEDGE®
150 mg
Capsules

Composition:
Each capsule contains: vismodegib 150 mg

* For information regarding inactive ingredients and allergens, see section 2 under "Important information about some of the ingredients of **Erivedge**" and section 6 "Further Information".

Read this leaflet carefully in its entirety before using the medicine. This leaflet contains concise information about the medicine. If you have further questions, refer to the doctor or pharmacist.

Keep this leaflet; you may need to read it again. This medicine has been prescribed for the treatment of your ailment. Do not pass it on to others. It may harm them even if it seems to you that their ailment is similar.

The medicine is not intended for children and adolescents under the age of 18.

1) IMPORTANT INFORMATION FOR YOUR ATTENTION

- **Erivedge** may cause birth defects and even death of the unborn or the newborn baby. Women able to become pregnant and men who are taking **Erivedge** must use contraceptive measures. Carefully read the sections relating to pregnancy, breastfeeding and fertility. The doctor will discuss this subject with you.

Patient safety information card and patient booklet: In addition to the leaflet, **Erivedge** comes with a patient booklet and patient card, which include important safety information that you must know and adhere to before starting and during treatment. Read them and the patient leaflet before commencing use of the medicine. Keep them for additional reading, if necessary.

- Do not donate sperm at any stage during the course of treatment and for 2 months after taking the final dose.
- Do not donate blood during the course of treatment with **Erivedge** and for 24 months after taking the final dose.
- Never **crush, open or chew** the capsule.
- **Erivedge** contains lactose.

What is the medicine intended for?
The medicine **Erivedge** contains the active ingredient vismodegib. **Erivedge** is a medicine used to treat adults with a type of skin cancer called basal cell carcinoma. **Erivedge** is given in cases when the cancer has spread to other parts of the body (metastatic) or when the cancer has spread to surrounding areas (locally advanced) and recurred after surgery or that it cannot be treated by surgery or radiation.

Therapeutic group: Anti-cancer.

Basal cell carcinoma develops when DNA in normal skin cells is damaged and the body cannot repair the damage. This damage can cause a change in the function of a number of proteins in the damaged cells and they become cancerous and begin to grow and divide. **Erivedge** is an anti-cancer medicine that binds and blocks one of the key proteins involved in this type of skin cancer. This action may slow or stop the cancer cells from growing, or enables their killing and, as a result, can lead to shrinkage of your skin cancer.

2) BEFORE USING THE MEDICINE

Do not use the medicine if:
- you are **allergic** to the active ingredient (vismodegib) or to any of the medicine's other ingredients (see section 6 "Further Information").
- you are **pregnant**, think you may be pregnant, or are planning to become pregnant during the course of treatment or during the 24 months after taking the final dose. This is because **Erivedge** may harm or cause the death of the unborn baby.
- you are **breastfeeding** or plan to breastfeed during the course of treatment or during the 24 months after taking the final dose. This is because it is not known whether **Erivedge** can pass into breast milk and harm your baby.
- you are capable of becoming pregnant and are unable to or refuse to follow the requirements for use of the necessary contraceptive measures (section 2 "Special warnings regarding use of the medicine").
- you are also taking *Hypericum perforatum* (St. John's wort) - an herbal medicine for treatment of depression.

For further information regarding pregnancy, see sections "Pregnancy, breastfeeding, fertility and contraception - for men and women".
Do not use this medicine if any of the above-mentioned conditions apply to you. If you are uncertain, consult a doctor or pharmacist before taking **Erivedge**.

Special warnings regarding use of the medicine
- Do not donate blood at any stage during the course of treatment and for 24 months after taking the final dose of this medicine.
- If you are a man, do not donate sperm at any stage during the course of treatment and for 2 months after taking the final dose.
- Serious skin reactions have been reported in association with **Erivedge** treatment. Stop using **Erivedge** and get medical attention immediately if you notice any of the symptoms described in section 4.
- Do not give this medicine to anyone else.

Children and adolescents
Erivedge is not intended for use in children and adolescents under 18 years of age. This is because the efficacy and safety of the medicine in this age group is unknown. **Erivedge** may cause the bones to stop growing and lead to premature onset of puberty (before age 8 years in girls or age 9 years in boys). This may occur also after discontinuing treatment with **Erivedge**. In studies conducted in animals who received the medicine, problems with growing teeth and bones were observed.

Erivedge and other medicines
If you are taking, or have recently taken, other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or pharmacist. Some medicines may affect how **Erivedge** works, or increase the risk of having side effects. **Erivedge** can also affect how other medicines work. Especially tell the doctor if you are taking any of the following medicines:
- rifampicin - for treatment of bacterial infections.
- carbamazepine, phenytoin - for treatment of epilepsy.
- ezetimibe and statins e.g., atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin - for treatment of high cholesterol.
- bosentan, glibenclamide, repaglinide, valsartan.
- topotecan - for treatment of certain types of cancer.
- sulfasalazine - for treatment of certain inflammatory disorders.
- *Hypericum perforatum* (St. John's wort) - an herbal medicine for treatment of depression. This medicine must not be taken during the treatment with **Erivedge**.

Use of the medicine and food
Erivedge can be taken with or without food.

Pregnancy
Do not take **Erivedge** if you are pregnant, think you may be pregnant, or are planning to become pregnant during the course of treatment or during the 24 months after taking the final dose. You must stop the treatment and inform the doctor immediately if a monthly period is delayed or you have unusual menstrual bleeding, or you suspect that you are pregnant.
If you became pregnant during the course of treatment with **Erivedge**, you must stop the treatment and inform the doctor immediately.
Erivedge may cause severe birth defects and even death of the unborn baby. The doctor will discuss this subject with you.

Breastfeeding
Do not breastfeed during the course of treatment or for 24 months after taking the final dose. It is not known if **Erivedge** can pass into your breast milk and harm your baby.

Fertility
Erivedge may affect a woman's ability to have children. Some women who took **Erivedge** stopped having periods. If this happens to you, it is not known if periods will come back again. Consult the doctor if you wish to have children in the future.

Contraception - for men and women
For women taking Erivedge
Before starting the treatment with **Erivedge**, check with the doctor if you are able to become pregnant. Even if your monthly periods have stopped, it is still important to ask the doctor if there is any risk that you could become pregnant.
If you are able to become pregnant:
- you need to use contraception so that you do not become pregnant during the course of treatment with **Erivedge**.
- use two different methods of contraception. One from the "highly effective" measures and an additional one from the "barrier measures" group (see examples below).
- you must continue using contraception for 24 months after taking the final dose, this is because the medicine may remain in your body for up to 24 months after taking the final dose.

Various types of recommended contraception: consult the doctor about the 2 types that are best for you.

Use one contraceptive from the group of "highly effective" contraceptives, such as:
- contraceptive injection
- an intra-uterine device
- surgical sterilization

In addition, you must use one measure from the group of "barrier" contraceptives, such as:
- a condom (with spermicide, if available)
- a diaphragm (with spermicide, if available)

The doctor will make sure that you will carry out a pregnancy test:
- during the 7 days before starting the treatment - to make sure that you are not already pregnant
- every month during the course of treatment

You must tell the doctor **immediately** if during the course of treatment or during the 24 months after taking the final dose:
- you think the contraception has failed for any reason.
- your monthly periods stop.
- you stopped using contraception.
- you have to switch the type of contraceptive.

For men taking Erivedge
Erivedge can pass into sperm. Always use a condom (with spermicide, if available) even after a vasectomy, when you have sexual intercourse with your female partner. Use this contraceptive measure during the course of treatment and for 2 months after taking the final dose of the medicine.
Do not donate sperm at any stage during the course of treatment and for 2 months after taking the final dose.

Driving and using machines
Erivedge is not expected to affect your ability to drive, use any tools or machines. Consult the doctor if you are uncertain.

Important information about some of the ingredients of Erivedge
Erivedge capsules contain a type of sugar called lactose. If you have been told by the doctor that you have an intolerance to certain sugars, consult the doctor before taking the medicine.
This medicine contains a negligible amount of sodium and is therefore considered to be "sodium-free".

3) HOW SHOULD YOU USE THE MEDICINE?

Always use according to the doctor's instructions. Check with the doctor or pharmacist if you are not sure about your dose or about how to take this medicine. The dosage and treatment regimen will be determined by the doctor only.

The usual dosage is generally one capsule per day. **Do not exceed the recommended dose**.

Swallow the capsule whole with water.

Never crush, open or chew the capsule to prevent unintended exposure to the contents of the capsule.

Erivedge can be taken with or without food.

If you have accidentally taken a higher dosage of Erivedge, consult your doctor.
If you have taken an overdose or if a child has accidentally swallowed the medicine, refer to the doctor or proceed to a hospital emergency room immediately and bring the package of the medicine with you.

If you forgot to take the medicine
If you forgot to take the medicine, do not take a double dose. Skip the forgotten capsule, and take the next dose at its scheduled time and consult the doctor.

If you stop taking the medicine
Adhere to the treatment regimen as recommended by the doctor. Do not stop taking the medicine without consulting the doctor; stopping treatment with the medicine may cause your treatment to be less effective.

Do not take medicines in the dark! Check the label and the dose each time you take the medicine. Wear glasses if you need them.

If you have any further questions regarding use of this medicine, consult the doctor or pharmacist.

4) SIDE EFFECTS

As with any medicine, use of **Erivedge** may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not suffer from any of them.

Erivedge may cause severe birth defects and even lead to the death of an unborn or newborn baby. Do not become pregnant during the course of treatment with the medicine (see section 2 "Do not use the medicine if", and the sections "Pregnancy", "Breastfeeding" and "Fertility").

Additional side effects
Very common side effects (effects that occur in more than 1 user in 10):
- loss of monthly periods in women of childbearing age
- loss of appetite and weight loss
- feeling tired
- muscle cramps
- diarrhea
- hair loss
- rash
- changes in the way things taste or the complete loss of taste
- constipation
- vomiting or nausea
- upset stomach or indigestion
- joint pain
- pain (general) or pain in the hands, legs
- itching

Common side effects (effects that occur in 1-10 in 100 users):
- pain in chest, back or side
- lack of energy or weakness
- loss of fluids from the body (dehydration)
- muscle, tendon, ligament, or bone pain
- abdominal pain
- loss of sense of taste
- abnormal hair growth
- eyelashes falling out
- changes in blood test results, including increased liver function values or increased creatinine phosphokinase (a protein mainly produced in the muscles) values

Side effects of unknown frequency (effects whose frequency has not yet been determined)
- bones that stop growing (premature fusion of the growth plates [epiphyses])
- premature puberty
- liver injury
- serious skin reactions:
  - reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These skin reactions are often preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).
  - widespread rash, fever, and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).
  - red, scaly widespread rash with bumps under the skin and blisters, accompanied by fever at the initiation of treatment (acute generalized exanthematous pustulosis).

If you experience any side effect, if any side effect gets worse, or if you suffer from a side effect not mentioned in the leaflet, consult with the doctor.

Side effects can be reported to the Ministry of Health by clicking on the "Reporting side effects following drug treatment" link found on the Ministry of Health homepage (www.health.gov.il) that directs you to the online form for reporting side effects or via the following link:
https://sideeffects.health.gov.il

5) HOW SHOULD THE MEDICINE BE STORED?

- Avoid poisoning! This medicine and any other medicine must be kept in a safe place out of the reach and sight of children and/or infants to avoid poisoning. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date (exp. date) that appears on the package and the bottle. The expiry date refers to the last day of that month, or after 12 months from first opening, whichever comes first.
- Do not store at a temperature above 30°C.
- Keep the bottle tightly closed in order to protect from moisture.
- Consult the pharmacist regarding disposal of medicines you are not using, in order to protect the environment.

6) FURTHER INFORMATION

Erivedge contains the active ingredient vismodegib. Each capsule contains 150 mg active ingredient.

In addition to the active ingredient, the medicine also contains:

Capsule contents: microcrystalline cellulose PH101, lactose monohydrate, sodium starch glycolate, povidone K29/32, sodium lauryl sulfate, talc, magnesium stearate (non-bovine).

Capsule shell: iron oxide red (E172), iron oxide black (E172), titanium dioxide, gelatin.

Printing ink: shellac glaze (20% esterified) and iron oxide black (E172).

Each **Erivedge** capsule contains 71.5 mg lactose.

What does the medicine look like and what are the contents of the package?
Erivedge is supplied as a capsule which consists of two parts, one part is pink with "150 mg" printed in black and a second part is grey with "VISMO" printed in black.

The package contains a bottle with a child-resistant screw cap, which contains 28 capsules.

License holder's name and address: Roche Pharmaceuticals (Israel) Ltd., P.O.B. 6391, Hod Hasharon 4524079.

Manufacturer's name and address: F. Hoffmann-La Roche Ltd., Basel, Switzerland.

This leaflet was revised in November 2020.

Registration number of the medicine in the National Drug Registry of the Ministry of Health: 149-22-33688-00.